Anvumetostat - Amgen
Alternative Names: AMG-193; MTA Cooperative PRMT5 inhibitorLatest Information Update: 28 Jun 2026
At a glance
- Originator Amgen
- Class Amides; Amines; Antineoplastics; Benzene derivatives; Ethers; Fluorine compounds; Fluorocarbons; Furans; Ketones; Morpholines; Naphthyridines; Small molecules
- Mechanism of Action PRMT5 protein inhibitors
-
Orphan Drug Status
Yes - Pancreatic cancer
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Biliary cancer; Gastrointestinal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 28 Jun 2026 Chemical structure information added
- 30 Apr 2026 Discontinued - Phase-I for Biliary cancer (Late-stage disease, Combination therapy, Inoperable/Unresectable, Metastatic disease) in USA (PO)
- 30 Apr 2026 Discontinued - Phase-I for Gastrointestinal cancer (Metastatic disease, Inoperable/Unresectable, Late-stage disease, Combination therapy) in USA (PO)